Discover
DMRA
Damora Therapeutics, Inc.
32.99
1 x 32.35
1 x 33.55
bid
ask
+
0.00
0.00%
2 @ 04:00 PM
32.34 -0.65 (1.97%)
| Ytd | 29.32% | |
| 1y | 29.32% |
31.94
day range
34.75
2.45
52 week range
38.33
| Open | 32.68 | Prev Close | 32.99 | Low | 31.94 | High | 34.75 | Mkt Cap | 2.03B |
| Vol | 436.64K | Avg Vol | 557.50K | EPS | -4.48 | P/E | -7.36 | Forward P/E | -14.82 |
| Beta | 1.46 | Short Ratio | 3.49 | Inst. Own | 91.38% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 25.15 | 200-d Avg | 23.00 | 1yr Est | 43.38 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-08-04 | 2026-06 | -0.38 | N/A | N/A | N/A |
| 2026-05-12 | 2026-03 | -0.21 | -0.62 | -0.41 | -195.24% |
| 2026-03-18 | 2025-12 | -0.14 | -3.24 | -3.1 | -2216.35% |
| 2025-08-05 | 2025-06 | 0 | -2.6 | N/A | N/A |
| 2025-05-08 | 2025-03 | 0 | -1.92 | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-06-12 | Wedbush | Upgrade | Outperform | Outperform |
| 2026-06-11 | HC Wainwright & Co. | Upgrade | Buy | |
| 2026-05-28 | Wedbush | Upgrade | Outperform | |
| 2026-04-24 | RBC Capital | Upgrade | Outperform | |
| 2026-03-25 | Evercore ISI Group | Upgrade | Outperform | |
| 2026-02-17 | UBS | Upgrade | Buy |
Profile
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-02-08 | BRUNO JULIANNE | Director | 137.03K | Conversion of Exercise of derivative security |
| 2026-02-08 | FAIRMOUNT FUNDS MANAGEMENT LLC | Director and Beneficial Owner of more than 10% of a Class of Security | 0.00 | Conversion of Exercise of derivative security |
| 2026-01-01 | FIRMANI LORI | Chief Financial Officer | 931.00 | Sale |
| 2026-01-04 | HEWES LEMUEL BECKER | Officer | 264.63K | Stock Award(Grant) |
| 2026-03-29 | JARRETT A JENNIFER | Chief Executive Officer | 500.00K | Stock Award(Grant) |
| 2026-01-04 | SATTARZADEH SHERWIN | Chief Operating Officer | 190.38K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | FMR, LLC | 9.05M | 278.42M | 14.70% |
| 2026-03-30 | Fairmount Funds Management LLC | 8.71M | 268.19M | 14.16% |
| 2026-03-30 | Avoro Capital Advisors LLC | 3.78M | 116.44M | 6.15% |
| 2026-03-30 | Venrock Adviser, LLC | 3.60M | 110.92M | 5.85% |
| 2026-03-30 | FCPM III Services B.V. | 2.44M | 75.13M | 3.97% |
| 2026-03-30 | RA Capital Management, L.P. | 2.40M | 73.85M | 3.90% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-05-30 | Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 1.83M | 56.29M | 2.97% |
| 2026-04-29 | Fidelity Securities Fund-Fidelity Small Cap Growth Fund | 834.04K | 25.67M | 1.35% |
| 2026-05-30 | Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund | 535.39K | 16.48M | 0.87% |
| 2026-05-30 | Fidelity Select Portfolios-Select Health Care Portfolio | 500.00K | 15.39M | 0.81% |
| 2026-05-30 | Fidelity Select Portfolios-Select Biotechnology Portfolio | 454.56K | 13.99M | 0.74% |
| 2026-05-30 | Fidelity Mt. Vernon Street Trust-Fidelity Series Growth Company Fund | 452.81K | 13.94M | 0.74% |